Antipsychotic Induced Metabolic Syndrome: Drug Emergent Metabolic Syndrome in Schizophrenic Patients Recieving Atypical Antipsychotics

Schizophrenia is definitely the most debilitating yet most enigmatic psychiatric illness. it changes the way a person perceive the world and the way the world perceive him. schizophrenia affects all the domains of personality - emotions, feelings, behaviour and mood but the central to the pathology is the defect in thought formation and processing. with the invention of chlorpromazine in 1952, a new era of pharmacological intervention arrived.today we have a huge basket of antipsychotic drugs to choose the perfect medicine for the individual patient. Due to lower rates of extra pyramidal side effects and other movement disorders as well as superior and potentially broader efficacy than conventional antipsychotics, atypical antipsychotics are widely prescribed for treatment of schizophrenia. Concerns about the adverse effects of atypical antipsychotics on weight regulation and glucose and lipid metabolism have led researchers to inquire whether the development of metabolic syndrome in otherwise healthy schizophrenic patients is the consequence of use of atypical antipsychotics